Eli Lilly said its tirzepatide franchise had another stellar quarter.

The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form of Wegovy as an alternative to obesity drugs given by injection.

The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive content. The daily pill, called Foundayo, is the second oral ...

A recent FDA approval means consumers now have two GLP-1 weight loss pills to choose from as an alternative to the traditional injections.

Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from obesity-related complications. The company has a diversified portfolio across weight management, neuroscience, and oncology, setting it ...

Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on April 6.

Novo Nordisk launched the high dose version of its GLP-1 injection at a price that’s $50 lower than the one for Eli Lilly’s competing drug.

The FDA proposed removing semaglutide and tirzepatide from a key compounding list, which could raise prices for millions of Americans using cheaper GLP-1 weight-loss drug alternatives.